Home > Research > Publications & Outputs > FcRn inhibitors for myasthenia gravis

Research

Links

Text available via DOI:

View graph of relations

FcRn inhibitors for myasthenia gravis

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

FcRn inhibitors for myasthenia gravis. / White, Laura M; Clay, Fiona J; Forbes, Anne-Marie et al.
In: Cochrane Database Syst. Rev., Vol. 8, No. 8, CD016097, 22.08.2025.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

White, LM, Clay, FJ, Forbes, A-M, Keh, RYS, Lilleker, JB, Spillane, J, Storms, K, Dodd, KC & Sussman, J 2025, 'FcRn inhibitors for myasthenia gravis', Cochrane Database Syst. Rev., vol. 8, no. 8, CD016097. https://doi.org/10.1002/14651858.cd016097

APA

White, L. M., Clay, F. J., Forbes, A.-M., Keh, R. Y. S., Lilleker, J. B., Spillane, J., Storms, K., Dodd, K. C., & Sussman, J. (2025). FcRn inhibitors for myasthenia gravis. Cochrane Database Syst. Rev., 8(8), Article CD016097. https://doi.org/10.1002/14651858.cd016097

Vancouver

White LM, Clay FJ, Forbes AM, Keh RYS, Lilleker JB, Spillane J et al. FcRn inhibitors for myasthenia gravis. Cochrane Database Syst. Rev. 2025 Aug 22;8(8):CD016097. doi: 10.1002/14651858.cd016097

Author

White, Laura M ; Clay, Fiona J ; Forbes, Anne-Marie et al. / FcRn inhibitors for myasthenia gravis. In: Cochrane Database Syst. Rev. 2025 ; Vol. 8, No. 8.

Bibtex

@article{a293c4432eee4b3aa9f734fc69a472f1,
title = "FcRn inhibitors for myasthenia gravis",
abstract = "This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of FcRn inhibitors for the maintenance treatment of myasthenia gravis in adult participants compared with control treatment (placebo, standard-of-care therapy, an alternative FcRn inhibitor, or an alternative immunomodulatory therapy). We will evaluate the efficacy of the treatment by the effect on disease severity and functional impairment, as assessed using a measurement tool validated for use in myasthenia gravis. Where possible, we will assess whether the effects of FcRn inhibitors differ according to different participant subgroups or different treatment regimens, or both. These data will be used to inform policymakers on the participant subgroups most likely to benefit from treatment and the most efficacious treatment regimen.",
author = "White, {Laura M} and Clay, {Fiona J} and Anne-Marie Forbes and Keh, {Ryan Yann Shern} and Lilleker, {James B} and Jennifer Spillane and Karen Storms and Dodd, {Katherine C} and Jon Sussman",
year = "2025",
month = aug,
day = "22",
doi = "10.1002/14651858.cd016097",
language = "English",
volume = "8",
journal = "Cochrane Database Syst. Rev.",
issn = "1465-1858",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - FcRn inhibitors for myasthenia gravis

AU - White, Laura M

AU - Clay, Fiona J

AU - Forbes, Anne-Marie

AU - Keh, Ryan Yann Shern

AU - Lilleker, James B

AU - Spillane, Jennifer

AU - Storms, Karen

AU - Dodd, Katherine C

AU - Sussman, Jon

PY - 2025/8/22

Y1 - 2025/8/22

N2 - This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of FcRn inhibitors for the maintenance treatment of myasthenia gravis in adult participants compared with control treatment (placebo, standard-of-care therapy, an alternative FcRn inhibitor, or an alternative immunomodulatory therapy). We will evaluate the efficacy of the treatment by the effect on disease severity and functional impairment, as assessed using a measurement tool validated for use in myasthenia gravis. Where possible, we will assess whether the effects of FcRn inhibitors differ according to different participant subgroups or different treatment regimens, or both. These data will be used to inform policymakers on the participant subgroups most likely to benefit from treatment and the most efficacious treatment regimen.

AB - This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of FcRn inhibitors for the maintenance treatment of myasthenia gravis in adult participants compared with control treatment (placebo, standard-of-care therapy, an alternative FcRn inhibitor, or an alternative immunomodulatory therapy). We will evaluate the efficacy of the treatment by the effect on disease severity and functional impairment, as assessed using a measurement tool validated for use in myasthenia gravis. Where possible, we will assess whether the effects of FcRn inhibitors differ according to different participant subgroups or different treatment regimens, or both. These data will be used to inform policymakers on the participant subgroups most likely to benefit from treatment and the most efficacious treatment regimen.

U2 - 10.1002/14651858.cd016097

DO - 10.1002/14651858.cd016097

M3 - Journal article

VL - 8

JO - Cochrane Database Syst. Rev.

JF - Cochrane Database Syst. Rev.

SN - 1465-1858

IS - 8

M1 - CD016097

ER -